Benitec Biopharma Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Benitec Biopharma Inc. (BNTC) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$124.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-09-14
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$11.00K.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$69.00K.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$133.00K, a 143.61% decline year-over-year.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $89.00K.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2026 was -$124.00K, a 333.96% decline from fiscal 2025.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $53.00K.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$62.00K, a 114.94% decline from fiscal 2023.
- Benitec Biopharma Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $415.00K, a 97.62% increase from fiscal 2022.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-14 | -$80.00K derived: sum of 2 quarters · filed 2026-09-14 | -$213.00K derived: sum of 3 quarters · filed 2026-09-14 | -$124.00K 10-K · filed 2026-09-14 |
| 2026-03-31 | -$69.00K 10-Q · filed 2026-05-14 | -$202.00K derived: sum of 2 quarters · filed 2026-05-14 | -$113.00K 10-Q · filed 2026-05-14 | -$236.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-12-31 | -$133.00K 10-Q · filed 2026-02-12 | -$44.00K 10-Q · filed 2026-02-12 | -$167.00K derived: sum of 3 quarters · filed 2026-03-20 | -$195.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-09-30 | $89.00K 10-Q · filed 2025-11-14 | -$34.00K derived: sum of 2 quarters · filed 2026-03-20 | -$62.00K derived: sum of 3 quarters · filed 2026-05-14 | $243.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2025-06-30 | -$123.00K 10-K/A · filed 2026-03-20 | -$151.00K derived: sum of 2 quarters · filed 2026-05-14 | $154.00K derived: sum of 3 quarters · filed 2026-05-14 | $53.00K 10-K · filed 2026-09-14 |
| 2025-03-31 | -$28.00K 10-Q · filed 2026-05-14 | $277.00K derived: sum of 2 quarters · filed 2026-05-14 | $176.00K 10-Q · filed 2026-05-14 | $119.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $305.00K 10-Q · filed 2026-02-12 | $204.00K 10-Q · filed 2026-02-12 | $147.00K derived: sum of 3 quarters · filed 2026-03-20 | $264.00K derived: sum of 4 quarters · filed 2026-03-20 |
| 2024-09-30 | -$101.00K 10-K/A · filed 2026-03-20 | -$158.00K derived: sum of 2 quarters · filed 2026-03-20 | -$41.00K derived: sum of 3 quarters · filed 2026-03-20 | -$213.00K derived: sum of 4 quarters · filed 2026-03-20 |
| 2024-06-30 | -$57.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-20 | $60.00K derived: sum of 2 quarters · filed 2026-03-20 | -$112.00K derived: sum of 3 quarters · filed 2026-03-20 | -$62.00K 10-K/A · filed 2026-03-20 |
| 2024-03-31 | $117.00K 10-Q · filed 2025-05-14 | -$55.00K derived: sum of 2 quarters · filed 2025-05-14 | -$5.00K 10-Q · filed 2025-05-14 | $18.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$172.00K 10-Q · filed 2025-02-14 | -$122.00K 10-Q · filed 2025-02-14 | -$99.00K derived: sum of 3 quarters · filed 2025-02-14 | -$54.00K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $50.00K 10-Q · filed 2024-11-14 | $73.00K derived: sum of 2 quarters · filed 2024-11-14 | $118.00K derived: sum of 3 quarters · filed 2024-11-14 | -$42.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $68.00K derived: sum of 2 quarters · filed 2024-09-26 | -$92.00K derived: sum of 3 quarters · filed 2024-09-26 | $415.00K 10-K · filed 2024-09-26 |
| 2023-03-31 | $45.00K 10-Q · filed 2024-05-13 | -$115.00K derived: sum of 2 quarters · filed 2024-05-13 | $392.00K 10-Q · filed 2024-05-13 | $653.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$160.00K 10-Q · filed 2024-02-13 | $347.00K 10-Q · filed 2024-02-13 | $608.00K derived: sum of 3 quarters · filed 2024-02-13 | $375.00K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | $507.00K 10-Q · filed 2023-11-13 | $768.00K derived: sum of 2 quarters · filed 2023-11-13 | $535.00K derived: sum of 3 quarters · filed 2023-11-13 | $478.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-21 | $28.00K derived: sum of 2 quarters · filed 2023-09-21 | -$29.00K derived: sum of 3 quarters · filed 2023-09-21 | $210.00K 10-K · filed 2023-09-21 |
| 2022-03-31 | -$233.00K 10-Q · filed 2023-05-15 | -$290.00K derived: sum of 2 quarters · filed 2023-05-15 | -$51.00K 10-Q · filed 2023-05-15 | $85.00K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$57.00K 10-Q · filed 2023-02-13 | $182.00K 10-Q · filed 2023-02-13 | $318.00K derived: sum of 3 quarters · filed 2023-02-13 | $294.00K derived: sum of 4 quarters · filed 2023-02-13 |
| 2021-09-30 | $239.00K 10-Q · filed 2022-11-10 | $375.00K derived: sum of 2 quarters · filed 2022-11-10 | $351.00K derived: sum of 3 quarters · filed 2022-11-10 | $559.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $136.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-02 | $112.00K derived: sum of 2 quarters · filed 2022-09-02 | $320.00K derived: sum of 3 quarters · filed 2022-09-02 | $498.00K 10-K · filed 2022-09-02 |
| 2021-03-31 | -$24.00K 10-Q · filed 2022-05-16 | $184.00K derived: sum of 2 quarters · filed 2022-05-16 | $362.00K 10-Q · filed 2022-05-16 | $1.14M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $208.00K 10-Q · filed 2022-02-14 | $386.00K 10-Q · filed 2022-02-14 | $1.17M derived: sum of 3 quarters · filed 2022-02-14 | $265.00K derived: sum of 4 quarters · filed 2022-02-14 |
| 2020-09-30 | $178.00K 10-Q · filed 2021-11-15 | $958.00K derived: sum of 2 quarters · filed 2021-11-15 | $57.00K derived: sum of 3 quarters · filed 2021-11-15 | $393.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $780.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-20 | -$121.00K derived: sum of 2 quarters · filed 2021-09-20 | $215.00K derived: sum of 3 quarters · filed 2021-09-20 | -$89.00K 10-K · filed 2021-09-20 |
| 2020-03-31 | -$901.00K 10-Q · filed 2021-05-12 | -$565.00K derived: sum of 2 quarters · filed 2021-05-12 | -$869.00K 10-Q · filed 2021-05-12 | |
| 2019-12-31 | $336.00K 10-Q · filed 2021-02-09 | $32.00K 10-Q · filed 2021-02-09 | ||
| 2019-09-30 | -$304.00K 10-Q · filed 2020-11-13 | |||
| 2019-06-30 | -$531.00K 10-K · filed 2020-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |